Durata Therapeutics, Inc. 4
4 · Durata Therapeutics, Inc. · Filed Nov 19, 2014
Insider Transaction Report
Form 4
FRIEDMAN PAUL A
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2014-11-17−8,575→ 0 totalExercise: $16.15Exp: 2024-05-20→ Common stock (8,575 underlying) - Disposition to Issuer
Stock Option (right to buy)
2014-11-17−11,145→ 0 totalExercise: $7.16Exp: 2023-05-15→ Common stock (11,145 underlying)
Footnotes (1)
- [F1]Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 5, 2014, by and among Durata Therapeutics, Inc., Actavis W.C. Holding Inc., and Delaware Merger Sub, Inc. (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each stock option and share of restricted stock that was outstanding and unexercised as of the Offer Acceptance Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive $23 per share (minus the exercise price of the option) in cash plus one CVR which represents the contractual right to receive up to $5.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.